Dear Customer, If you experience any text readability or display issues on our website, please update your web browser to the latest version
.
See More
Dear Customer, If you experience any text readability or display issues on our website, please update your web browser to the latest version
.
See MoreDear Customer, If you experience any text readability or display issues on our website, please update your web browser to the latest version
.
This page has been recently translated and is available in French now.
Looks like you're visiting us from {countryName}.
Would you like to stay on the current location site or be switched to your location?
Analysis of Stat1 (pS727) in human epithelioid carcinoma and peripheral blood lymphocytes. HeLa S3 cells (left panel, ATCC CCL 2.2) were either treated with 0.5 μg/ml Nocodazole (Sigma-Aldrich, Cat. No. M1404) at 37°C for 18 hours (dashed line) or untreated (solid line). Human peripheral blood mononuclear cells (middle panel) were either stimulated with 50 nM PMA (Sigma, P8139) for 15 minutes at 37ºC (shaded histogram) or untreated (open histogram). The cells were fixed (BD Cytofix™ buffer, Cat. No. 554655) for 10 minutes at 37°C, permeabilized (BD Phosflow™ Perm Buffer III, Cat. No. 558050) on ice for 30 minutes, and then stained with Alexa Fluor® 647 Mouse anti-Stat1 (pS727, Cat. No. 560190). Flow cytometry was performed on a BD™ LSR II (left) or FACSCalibur (middle) flow cytometer, and lymphocytes were identified by their scatter profile. The right panel shows confirmation of the specificity by western blot using unconjugated K51-856 antibody at 2.0 μg/ml on lysates from PMA-treated (lane 1, left blot) and control (lane 2) PBMCs and Nocodazole-treated (lane 1, right blot) and control (lane 2) HeLa S3 cells. Stat1 (pS727) is identified as a band of 91 kDa in the treated cells.
Analysis of Stat1 (pS727) in human epithelioid carcinoma and peripheral blood lymphocytes. HeLa S3 cells (left panel, ATCC CCL 2.2) were either treated with 0.5 μg/ml Nocodazole (Sigma-Aldrich, Cat. No. M1404) at 37°C for 18 hours (dashed line) or untreated (solid line). Human peripheral blood mononuclear cells (middle panel) were either stimulated with 50 nM PMA (Sigma, P8139) for 15 minutes at 37ºC (shaded histogram) or untreated (open histogram). The cells were fixed (BD Cytofix™ buffer, Cat. No. 554655) for 10 minutes at 37°C, permeabilized (BD Phosflow™ Perm Buffer III, Cat. No. 558050) on ice for 30 minutes, and then stained with Alexa Fluor® 647 Mouse anti-Stat1 (pS727, Cat. No. 560190). Flow cytometry was performed on a BD™ LSR II (left) or FACSCalibur (middle) flow cytometer, and lymphocytes were identified by their scatter profile. The right panel shows confirmation of the specificity by western blot using unconjugated K51-856 antibody at 2.0 μg/ml on lysates from PMA-treated (lane 1, left blot) and control (lane 2) PBMCs and Nocodazole-treated (lane 1, right blot) and control (lane 2) HeLa S3 cells. Stat1 (pS727) is identified as a band of 91 kDa in the treated cells.
Analysis of Stat1 (pS727) in human epithelioid carcinoma and peripheral blood lymphocytes. HeLa S3 cells (left panel, ATCC CCL 2.2) were either treated with 0.5 μg/ml Nocodazole (Sigma-Aldrich, Cat. No. M1404) at 37°C for 18 hours (dashed line) or untreated (solid line). Human peripheral blood mononuclear cells (middle panel) were either stimulated with 50 nM PMA (Sigma, P8139) for 15 minutes at 37ºC (shaded histogram) or untreated (open histogram). The cells were fixed (BD Cytofix™ buffer, Cat. No. 554655) for 10 minutes at 37°C, permeabilized (BD Phosflow™ Perm Buffer III, Cat. No. 558050) on ice for 30 minutes, and then stained with Alexa Fluor® 647 Mouse anti-Stat1 (pS727, Cat. No. 560190). Flow cytometry was performed on a BD™ LSR II (left) or FACSCalibur (middle) flow cytometer, and lymphocytes were identified by their scatter profile. The right panel shows confirmation of the specificity by western blot using unconjugated K51-856 antibody at 2.0 μg/ml on lysates from PMA-treated (lane 1, left blot) and control (lane 2) PBMCs and Nocodazole-treated (lane 1, right blot) and control (lane 2) HeLa S3 cells. Stat1 (pS727) is identified as a band of 91 kDa in the treated cells.
Analysis of Stat1 (pS727) in human epithelioid carcinoma and peripheral blood lymphocytes. HeLa S3 cells (left panel, ATCC CCL 2.2) were either treated with 0.5 μg/ml Nocodazole (Sigma-Aldrich, Cat. No. M1404) at 37°C for 18 hours (dashed line) or untreated (solid line). Human peripheral blood mononuclear cells (middle panel) were either stimulated with 50 nM PMA (Sigma, P8139) for 15 minutes at 37ºC (shaded histogram) or untreated (open histogram). The cells were fixed (BD Cytofix™ buffer, Cat. No. 554655) for 10 minutes at 37°C, permeabilized (BD Phosflow™ Perm Buffer III, Cat. No. 558050) on ice for 30 minutes, and then stained with Alexa Fluor® 647 Mouse anti-Stat1 (pS727, Cat. No. 560190). Flow cytometry was performed on a BD™ LSR II (left) or FACSCalibur (middle) flow cytometer, and lymphocytes were identified by their scatter profile. The right panel shows confirmation of the specificity by western blot using unconjugated K51-856 antibody at 2.0 μg/ml on lysates from PMA-treated (lane 1, left blot) and control (lane 2) PBMCs and Nocodazole-treated (lane 1, right blot) and control (lane 2) HeLa S3 cells. Stat1 (pS727) is identified as a band of 91 kDa in the treated cells.
Analysis of Stat1 (pS727) in human epithelioid carcinoma and peripheral blood lymphocytes. HeLa S3 cells (left panel, ATCC CCL 2.2) were either treated with 0.5 μg/ml Nocodazole (Sigma-Aldrich, Cat. No. M1404) at 37°C for 18 hours (dashed line) or untreated (solid line). Human peripheral blood mononuclear cells (middle panel) were either stimulated with 50 nM PMA (Sigma, P8139) for 15 minutes at 37ºC (shaded histogram) or untreated (open histogram). The cells were fixed (BD Cytofix™ buffer, Cat. No. 554655) for 10 minutes at 37°C, permeabilized (BD Phosflow™ Perm Buffer III, Cat. No. 558050) on ice for 30 minutes, and then stained with Alexa Fluor® 647 Mouse anti-Stat1 (pS727, Cat. No. 560190). Flow cytometry was performed on a BD™ LSR II (left) or FACSCalibur (middle) flow cytometer, and lymphocytes were identified by their scatter profile. The right panel shows confirmation of the specificity by western blot using unconjugated K51-856 antibody at 2.0 μg/ml on lysates from PMA-treated (lane 1, left blot) and control (lane 2) PBMCs and Nocodazole-treated (lane 1, right blot) and control (lane 2) HeLa S3 cells. Stat1 (pS727) is identified as a band of 91 kDa in the treated cells.
Analysis of Stat1 (pS727) in human epithelioid carcinoma and peripheral blood lymphocytes. HeLa S3 cells (left panel, ATCC CCL 2.2) were either treated with 0.5 μg/ml Nocodazole (Sigma-Aldrich, Cat. No. M1404) at 37°C for 18 hours (dashed line) or untreated (solid line). Human peripheral blood mononuclear cells (middle panel) were either stimulated with 50 nM PMA (Sigma, P8139) for 15 minutes at 37ºC (shaded histogram) or untreated (open histogram). The cells were fixed (BD Cytofix™ buffer, Cat. No. 554655) for 10 minutes at 37°C, permeabilized (BD Phosflow™ Perm Buffer III, Cat. No. 558050) on ice for 30 minutes, and then stained with Alexa Fluor® 647 Mouse anti-Stat1 (pS727, Cat. No. 560190). Flow cytometry was performed on a BD™ LSR II (left) or FACSCalibur (middle) flow cytometer, and lymphocytes were identified by their scatter profile. The right panel shows confirmation of the specificity by western blot using unconjugated K51-856 antibody at 2.0 μg/ml on lysates from PMA-treated (lane 1, left blot) and control (lane 2) PBMCs and Nocodazole-treated (lane 1, right blot) and control (lane 2) HeLa S3 cells. Stat1 (pS727) is identified as a band of 91 kDa in the treated cells.
Any use of products other than the permitted use without the express written authorization of Becton, Dickinson and Company is strictly prohibited.
Either BD Cytofix™ fixation buffer or BD Phosflow™ Fix Buffer I may be used for cell fixation. Any of the three BD Phosflow™ permeabilization buffers may be used.
Stat (Signal transducer and activators of transcription) proteins are critical mediators of the biologic activity of cytokines, including interleukins, interferons, erythropoietin, and growth factors. Ligand-receptor interaction leads to activation of constitutively associated JAK family kinases and subsequent recruitment/activation of Stat proteins by tyrosine phosphorylation. Active Stat proteins then move to the nucleus to promote transcription of cytokine-inducible genes. Seven Stat proteins have been cloned, each of which is differentially expressed and/or activated in a cytokine-specific and cell type-specific manner. Stat1 and Stat2 are components of the ISGF3 (Interferon-Stimulated Gene Factor 3) complex, which is the primary transcription activator induced by the binding of the interferon to a specific cell-surface receptor. Stat1 has two alternatively spliced isoforms, 91-kDa Stat1α and 84-kDa Stat1β; Stat1α has 38 additional C-terminal amino acids. In response to the binding of IFNα, IFNγ, EGF, PDGF, or CSF-1 to their respective receptors, the Stat1 subunits become tyrosine-phosphorylated at Y701, and the complex is translocated to the nucleus. This results in the formation of an active complex that includes the DNA-binding p48 subunit. This complex is responsible for modulating the transcription of the interferon-stimulated genes (ISGs). Furthermore, phosphorylation of serine 727 (S727) of Stat1 may occur in response to pathogens, cytokines, UV irradiation, and engagement of T and B cell antigen receptors. This second phosphorylation event is necessary for fully effective activation of transcription and may differentially regulate gene activation by interacting with other regulatory factors, such as p53 in the apoptotic pathway.
The K51-856 monoclonal antibody recognizes the phosphorylated S727 in the C-terminal transactivating domain of human Stat1α; this site is not present in Stat1β.
Please refer to Support Documents for Quality Certificates
Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described
Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims. Comparisons are not made against non-BD technologies, unless otherwise noted.
For Research Use Only. Not for use in diagnostic or therapeutic procedures.